Sir, Avibactam is a non-b-lactam inhibitor of class A, class C and some class D active-site serine b-lactamases. 1 -3 On the basis of the Research letters structural analysis of the avibactam binding mode in class C enzymes and MIC determinations, Lahiri et al. 4 suggested, in a recent paper, that the Enterobacter cloacae CHE b-lactamase was less sensitive to inhibition by avibactam than the P99 enzyme, from which it differs mainly by a six-residue deletion in the H-10 helix in addition to four other mutations, 5 which did not appear to be involved in the sensitivity differences.
In this letter we present direct measurements of the interaction between avibactam and the CHE enzyme that confirm the decreased sensitivity suggested by Lahiri et al.
4
The production and purification of the enzyme will be described elsewhere. The analysis of the kinetic results was based on the two-step model:
where E is the enzyme, A is avibactam, EA is a non-covalent complex (dissociation constant K), EA* is the covalent adduct and k +2 and k 22 are first-order rate constants. Unless otherwise stated, all experiments were performed at 308C in 100 mM HEPES, pH 7.5, containing 0.2 M NaCl and 50 mg/mL BSA when the enzyme was diluted to ,2.5 mM. The pseudo-first-order rate constants for inactivation (k i , see below) were determined by mixing the enzyme (6 nM) with avibactam (60 -140 mM) and nitrocefin (58 mM). Hydrolysis of the reporter substrate (nitrocefin) was monitored at 482 nm for 40 min. The k i values were deduced from the hydrolysis curves as described by De Meester et al. 6 At the highest avibactam concentration, the k i value was 1 Figure 1 ). Note that the general expression for k i is:
(where K ′ is the apparent dissociation constant, which differs from K as explained below), but, in all cases, k 22 was negligible when compared with the second term of the right side of the equation. To obtain the K value, K ′ must be corrected for the protection of the enzyme by the reporter substrate, nitrocefin, whose K m was 9.4+1 mM (A. Fernea, M. Galleni and J.-M. Frè re, unpublished results). 
To determine the k 22 value, 5 mM enzyme was incubated for 20 min with 250 mM avibactam. The excess of avibactam was eliminated by rapid (15 min) molecular sieve chromatography at 218C. The enzyme concentration in the conserved fractions of the protein peak was estimated at 0.34 mM. A sample was diluted 10-fold and incubated at 308C. After 3, 24, 48 and 120 h, 50 mL aliquots were withdrawn and the recovered activity was determined by adding 450 mL of 30 mM nitrocefin. The value after 120 h was taken as 100%, which yielded a k 22 value of 1.3+0.15×10
25 s 21 (half-life ¼ 15+2 h), on the basis of a single exponential decay of EA* (indeed, under these conditions it can be considered that EA* directly decays into E + A without significant accumulation of EA). A control sample exhibited only a minor loss of activity ( 10%) over the same period of time.
The global equilibrium constant (K eq ¼ k 22 ×K/k +2 ) was determined by incubating 0.5 mM enzyme with 5 mM avibactam for 20 h. The residual activity was 2.1+0.2%, from which a K eq value of 0.1+0.01 mM could be deduced. On the basis of the individual k +2 , k 22 and K values determined above, the calculated K eq value is 0.065+0.018 mM, in good agreement with the direct measurement.
By 25 s 21 and K eq ¼ 2 nM (the difference is mainly due to the k 22 values). In consequence, the CHE enzyme exhibits a significantly decreased sensitivity to avibactam: 25-to 30-fold on the basis of the k +2 /K values and 10-to 30-fold on the basis of the K eq values. Note that, by contrast, the k 22 values only differ by a factor of at most 3. Our results are thus in complete agreement with the suggestion of Lahiri et al., 4 although one cannot be completely sure that the different sensitivities are only due to the deletion or whether one or more of the other four mutations are also involved.
To our knowledge, the CHE enzyme, which is considered to be an extended-spectrum AmpC (ESAC) b-lactamase, has only been observed once. 5 Other ESAC enzymes, which do not present the six-residue deletion, seem to have retained full sensitivity to avibactam. 7 One can only hope that the CHE-type deletion will remain rare and that the clinical utilization of avibactam will not result in the selection of mutants exhibiting a decreased sensitivity to this inactivator due to the same or similar mutations in the same region of the protein. Sir, Ceftaroline is a cephalosporin antibiotic indicated for the treatment of acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia. 1 Ceftaroline has been used for non-FDA-approved indications, including osteomyelitis, endocarditis, bacteraemia and epidural abscesses.
2 -5 Data on use for meningitis are limited to two rabbit models, showing penetration into CSF of 14% -15% in inflamed meninges and 3% in uninflammed meninges. 6, 7 The distribution of drugs into the CSF is dependent upon multiple factors, including their lipophilicity, plasma protein binding and molecular size, and the affinity of active transport mechanisms to remove them from the CNS. 8 Ceftaroline has low protein binding, is hydrophilic and has a similar volume of distribution to other cephalosporins. 1 Cephalosporins distribute into the CSF relatively poorly, averaging AUC CSF /AUC serum ratios of 0.007-0.1 for uninflamed or mildly inflamed meninges and 0.15 for strongly inflamed meninges. However, due to their potency, many cephalosporins achieve therapeutic CSF concentrations. 8 We report a case of ceftaroline for the treatment of MRSA meningitis related to an infected ventriculoperitoneal (VP) shunt. This case report was reviewed and approved by our Institutional Review Board.
A patient presented with altered mental status and lethargy for 24 h. The patient had a history of hydrocephalus with chronic VP shunt placement and 1 month prior had undergone shunt replacement due to infection with methicillin-resistant Staphylococcus epidermidis, which was treated with vancomycin.
On presentation, vitals were stable. However, the patient suddenly desaturated to 40% oxygen on room air and was intubated. The white blood cell count was 23.6/mm 3 with 93% segmented neutrophils and 4% bands. Arterial blood gas results were pH 7.55, pCO 2 29 mmHg, pO 2 216 mmHg and HCO 3 25.4 mmol/L. Serum creatinine was 0.5 mg/dL, which remained stable with an estimated creatinine clearance of .100 mL/min throughout admission. A CT scan showed new prominent dilatation of the lateral ventricles. The patient was diagnosed with obstructive hydrocephalus and taken to the operating room. Cefazolin was administered for surgical prophylaxis and a proximal shunt malfunction was addressed with insertion of a new proximal catheter. CSF was drawn from the shunt and sent for culture. The patient was transferred to the ICU.
On day 1 of admission, the CSF Gram stain report showed Gram-positive cocci in pairs and clusters. Fluid count was not completed. Infectious diseases consultation was requested for meningitis. On day 2, the patient became febrile at 39.18C and was taken to the operating room for removal of the shunt and placement of an external ventricular drain. A repeat CSF culture and the VP shunt tip were sent for analysis. The patient was started on linezolid, ceftriaxone and nafcillin and then switched to 600 mg of ceftaroline intravenously every 8 h on day 3. Vancomycin was avoided given recent use and concern for treatment failure. The CSF culture from day 1 was finalized as MRSA with a ceftaroline MIC¼ 1.0 mg/L by Etest w . The CSF culture from day 2 was finalized as negative, while the shunt tip grew MRSA. By the time of finalization, the patient had been started on ceftaroline and had additional repeat CSF cultures that were negative so ceftaroline was continued. Due to the lack of data on the use of ceftaroline for meningitis, samples of
